Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hormone Replacement in Menopausal Women With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00027209
Recruitment Status : Completed
First Posted : November 29, 2001
Last Update Posted : May 15, 2006
Sponsor:
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS)

Tracking Information
First Submitted Date  ICMJE November 28, 2001
First Posted Date  ICMJE November 29, 2001
Last Update Posted Date May 15, 2006
Study Start Date  ICMJE Not Provided
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE Not Provided
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Hormone Replacement in Menopausal Women With Epilepsy
Official Title  ICMJE Not Provided
Brief Summary The goal of this study is to evaluate the effect of synthetic hormone replacement therapy on anti-seizure medication levels, menopausal symptom relief, and seizure frequency and safety in menopausal women with epilepsy.
Detailed Description This study will help to answer questions regarding the use of hormone replacement therapy that women with epilepsy face as they reach menopause. The total duration of the study is 6 months and involves 7 visits to the doctor. The purposes of the study are to discover if and how menopause and treatments for the symptoms of menopause change epilepsy in women, to determine which if any factors present before and/or during menopause may predict the influence of menopause on a woman's seizure disorder, and to find any possible interactions between hormone replacement therapy and anti-seizure medication in order to find the optimal dose of hormone replacement therapy for women with epilepsy.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE
  • Menopause
  • Epilepsy
Intervention  ICMJE Drug: prempro
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: June¬†23,¬†2005)
125
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects must have a diagnosis of partial epilepsy which has predated the onset of menopause.
  • Subjects must have between 0-10 seizures of any type per month.
  • Subjects must have had an EEG consistent with a partial epilepsy diagnosis, showing a focal abnormality.
  • Subjects must have had an imaging study of the brain since the diagnosis of epilepsy.
  • Subjects must be 1 year menopausal (without their menstrual periods), but within 5 years of their last menstrual period.
  • Subjects must be medically cleared by their primary care physician to take HRT.
  • Subjects must have had a normal PAP smear within the past 9 months.
  • Subjects must have had a mammogram without lesions suspicious for malignancy within the past 9 months.
  • Subjects or their caregivers must be able to keep an accurate seizure diary.
  • Subjects must be stable on their current AEDs for >1 month.
  • Subjects must have not used HRT during the 3 months prior to enrollment.

Exclusion Criteria:

  • Subjects with a history of breast, uterine or ovarian cancer.
  • Subjects with a treatable or reversible cause of recurrent seizures (metabolic, neoplastic, toxic or infectious causes).
  • Subjects with a history of deep vein thrombosis, arterial thrombosis, pulmonary embolus, blood clotting disorders, or stroke.
  • Subjects with elevated liver function test more than two time normal.
  • Subjects with 3 first degree family members who have a history of breast cancer.
  • Subjects with 1 first degree family member with a history of bilateral breast cancer.
  • Subjects with a history of complicated migraine headaches.
  • Subjects with a history of unexplained vaginal bleeding.
  • Subjects with a history of familial hyperlipoproteinemia.
  • Subjects with a history of myocardial infarction in the past 6 months.
  • Subjects with diabetes mellitus with vascular disease.
  • Subjects with untreated hypertension (>145/95 on 3 occasions).
  • Subjects with a history of using an experimental drug or device in the past 30 days.
  • Subjects with severe chronic and/or progressive medical illnesses.
  • Subjects with active drug and alcohol abuse.
  • Subjects with a history of discontinuation of Prempro in the past due to side effects.
  • Subjects who state that they cannot tolerate 6 more months without relief of menopausal symptoms.
  • Subjects who plan to change or anticipate a change in their antiseizure treatment in the next 6 months.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00027209
Other Study ID Numbers  ICMJE R01NS038473( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE National Institute of Neurological Disorders and Stroke (NINDS)
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account National Institute of Neurological Disorders and Stroke (NINDS)
Verification Date November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP